New injection therapy for hemophilia A, Frehemgo, wins approval in Europe
Preventive treatment aims to cut bleeding episodes in adults and children
Written by |
The preventive therapy Frehemgo for hemophilia A is now approved for use in the European Union. (Image from iStock)
- The prophylaxis denecimig has been approved in the EU, under the brand name Frehemgo, to prevent bleeding episodes in hemophilia A.
- The treatment will soon be available for use by adults and children with the bleeding disorder, regardless of inhibitor status.
- Frehemgo offers flexible dosing options — monthly, every two weeks, or weekly — for people with and without inhibitors to treatment.
The injection therapy denecimig for hemophilia A — designed to prevent bleeding episodes in adults and children with or without inhibitors — has been approved in the European Union and will soon be marketed under the brand name Frehemgo.
Developer Novo Nordisk announced in a company press release that the European Commission granted marketing authorization to Frehemgo, clearing the medication for use in EU member states. Novo said the drug, given via a single-use pre-filled pen, will be launched in the first countries in Europe in the coming year.
According to the developer, Frehemgo is now the first hemophilia treatment of its kind to offer once-monthly, once-every-two-weeks, and once-weekly treatment options for people living with hemophilia A.
Approval of Frehemgo in Europe comes on the heels of a positive recommendation from a branch of the European Medicines Agency. Frehemgo has also been approved in Saudi Arabia, and the U.S. Food and Drug Administration (FDA) is now reviewing an application seeking similar approval in the U.S.
Martin Holst Lange, chief scientific officer and executive vice president of research and development at Novo, said that the European approval is “the result of many years of work by our scientists, the trial investigators and the people with haemophilia A who took part in our studies. Together, they have helped bring the haemophilia community a treatment option that minimises trade-offs in care.”
A genetic disorder, hemophilia A is marked by a deficiency of the clotting protein factor VIII. Without this protein, blood doesn’t clot properly, leading to hemophilia symptoms such as easy bleeding.
Standard treatment involves factor replacement therapy, in which a functional version of the FVIII protein is administered to control bleeding. However, some patients develop inhibitors, which are antibodies that stick to factor VIII protein and reduce the effectiveness of such replacement therapies.
Frehemgo given with injector pen
Frehemgo, also previously known as Mim8, is an antibody-based therapy designed to mimic the activity of the factor VIII protein. It essentially restores function without using the protein itself, thereby preventing bleeding while avoiding targeting by inhibitors.
The new European approval of Frehemgo was based largely on data from two Phase 3 trials: FRONTIER2 (NCT05053139), which enrolled adults and adolescents, and FRONTIER3 (NCT05306418), which enrolled younger children. Across both trials and an extension study dubbed FRONTIER4 (NCT05685238) — which evaluated the therapy over long-term use — Frehemgo was shown to effectively limit bleeding with an acceptable safety profile.
Lange said the European approval of Frehemgo “reflects the strength and consistency of the FRONTIER programme, which showed strong bleed protection across adults and children, with and without inhibitors.”
Each advance in treatment gives people with haemophilia and their families more freedom to focus on other aspects of life.
Novo’s application for EU approval also included data from another Phase 3 study, FRONTIER5 (NCT05878938). That trial enrolled people with hemophilia A who had previously been taking Hemlibra (emicizumab-kxwh), an approved treatment from Roche that similarly uses an antibody to mimic the activity of factor VIII protein.
The results from FRONTIER5 showed that patients could safely switch from Hemlibra to Frehemgo. Further, trial participants said the injector pen used to administer Frehemgo subcutaneously, or under the skin, was easy to use.
Maria Elisa Mancuso, MD, medical member of the board of directors of the World Federation of Hemophilia, applauded the EU approval of Frehemgo.
“Living with haemophilia means constantly planning around the risk of bleeding, often from early childhood. Each advance in treatment gives people with haemophilia and their families more freedom to focus on other aspects of life,” Mancuso said. “Having more treatment options to discuss with their clinicians allows people to consider what best fits their everyday lives — at school, at work, in sport and within their families — and make informed decisions that reflect their individual needs and priorities.”

Leave a comment
Fill in the required fields to post. Your email address will not be published.